Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
165.73(c) 169.12(c) 172.37(c) 173.01(c) 171.9633 Last
651 260 703 346 1 230 425 1 272 756 653 352 Volume
-1.78% +2.05% +1.92% +0.37% -0.61% Change
More quotes
Financials (USD)
Sales 2019 3 566 M
EBIT 2019 1 415 M
Net income 2019 858 M
Finance 2019 4 066 M
Yield 2019 -
Sales 2020 4 421 M
EBIT 2020 2 111 M
Net income 2020 1 251 M
Finance 2020 4 673 M
Yield 2020 -
P/E ratio 2019 53,63
P/E ratio 2020 36,73
EV / Sales2019 11,3x
EV / Sales2020 8,97x
Capitalization 44 312 M
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.7%); - royalties and... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
05/15VERTEX PHARMACEUTICALS : and Kymera Therapeutics Establish Strategic Collaborati..
BU
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
05/01VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
05/01VERTEX PHARMACEUTICALS : FDA Approves Kalydeco for Infants with CF
AQ
05/01VERTEX PHARMACEUTICALS : FDA Approves KALYDECO as First and Only CFTR Modulator ..
AQ
04/30VERTEX : 1Q Earnings Snapshot
AQ
04/30VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
04/30VERTEX PHARMACEUTICALS : Reports First-Quarter 2019 Financial Results
BU
04/30VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® (ivacaftor) as First and Only CF..
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Bio Therapeutic Drugs
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 209 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Paul M. Silva Chief Financial Officer, Controller & Senior VP
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Bruce I. Sachs Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS4.41%44 312
GILEAD SCIENCES7.39%84 558
REGENERON PHARMACEUTICALS-15.59%34 482
GENMAB12.69%11 076
SAREPTA THERAPEUTICS INC8.36%9 019
BEIGENE LTD--.--%7 637